Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06907992 · ClinicalTrials.gov registry record
A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia
A clinical trial, sponsored by Augusta University.
- Not yet
- Registry status
- 150
- Enrollment target
NCT06907992: Clinical Trial study, sponsored by Augusta University.
NCT06907992 is a clinical trial that has not yet begun recruiting, run by Augusta University. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06907992 has not yet begun recruiting, sponsored by Augusta University.
- NOT YET RECRUITING
- Registry status
- 150 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess whether a seven-day course of standard of care (echinocandin) antifungal therapy is non-inferior to a 14-day course of echinocandin antifungal therapy in patients with uncomplicated candidemia in terms of clinical, mycologic, adverse events and all cause mortality.
Primary Outcome
Blood culture monitoring at day 7 and day 14
Interventions
- DRUG Antifungal treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2027-12-31 |
What is known before NCT06907992 opens enrollment
NCT06907992 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Antifungal treatment is the first listed.
NCT06907992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06907992 about?
NCT06907992 is a clinical study titled "A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia". The goal of this clinical trial is to assess whether a seven-day course of standard of care (echinocandin) antifungal therapy is non-inferior to a 14-day course of echinocandin antifungal therapy in patients with uncomplicated candidemia in terms of clinical, mycologic, adverse events and all cause ...
What is the current status of trial NCT06907992?
This trial is currently not yet recruiting. The enrollment target is 150 participants. The study started on 2025-05-01. Estimated completion is 2027-12-31.
What interventions are being tested in trial NCT06907992?
The interventions under investigation include: Antifungal treatment (DRUG).
Who is sponsoring clinical trial NCT06907992?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI